Jintai Holdings' stock rises over 7% after earnings, achieving an annual revenue of 803 million yuan, a year-on-year increase of 201.25%

robot
Abstract generation in progress

Jintai Holdings (02228) rose over 7% after earnings release. As of the time of writing, the stock price increased by 6.94%, currently trading at HKD 9.71, with a turnover of HKD 257 million.

Jintai Holdings announced its annual results, achieving a revenue of RMB 803 million for the year, a significant year-on-year increase of 201.25%. Net profit for the period was RMB 124 million, turning from loss to profit year-on-year, marking its first full-year profit. The group’s first-ever annual profit also makes it the first Hong Kong-listed company in the AI for Science field to be profitable.

Public information shows that by 2025, Jintai Holdings will continue to focus on “AI for Science.” While antibody business is rapidly growing, the company has successfully expanded into multimodal innovative platforms such as peptides, molecular glues, and nucleic acids. This has driven the development of enabling services and incubation of innovative enterprises, gradually entering the verification stage. The multiple breakthroughs in business have allowed Jintai, which is continuously deepening its “AI for Science” platform, to officially enter the period of “hardcore innovation—commercialization—performance validation” for value realization.

(Edited by: Liu Jing HZ010)

【Disclaimer】This article only reflects the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions in the article and does not provide any explicit or implied guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use it for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin